eResearch Technology, Inc. Signs a $3 Million Contract to Supply US Oncology, Inc. with its Integrated Suite of Software and Services for Speeding Drug Development in Clinical Research

eResearch Technology (eRT), a leading e-research technkology and services provider to the pharmaceutical, biotechnology and medical device industries. eRT announced today a 3-year, $3 Million contract with US Oncology, Inc., one of the nation's most extensive oncology networks, with an integrated electronic solution to which will help manage clinical research studies. US Oncology will axquire eRT's electronic research network and community technology along with a full complement of application service provider services to ensure its rapid deployment. eRT's applications will expedite clinical drug development while producing quality data in a validated environment.

CONTACT:

Joni Sterlacci                
eResearch Technology, Inc.
908/704-8010 x134

Matthew Hayden
Hayden Communications, Inc.
843/272-4653

eRT further penetrates the Oncology arena offering its eResearch Network and Community Technology to the nations most extensive oncology network

PHILADELPHIA, PA -- April 30, 2001 -- eResearchTechnology, Inc. (eRT), (NASDAQ: ERES), a leading e-research technology and services provider announced today a three year, $3 Million contract with US Oncology, Inc. (NASDAQ:USON), to acquire eRTs electronic research network (eResNetTM) and community (eResComTM) technology along with a full complement of application service provider (ASP) services to ensure its rapid deployment.

The eResNet technology will allow US Oncology to build an integrated electronic research network that accelerates the collection, processing, and presentation of their clients clinical data that is obtained from their network of community-based cancer physicians, patients, clinicians, nurses, and administrators," stated Joseph Esposito, President and CEO of eRT.

eRTs technology will enable US Oncology to leverage our scientific capabilities and physician network to pursue our growth strategies in research, drug development, bio-informatics, and new diagnostic services." said Atul Dhir, M.D., D.Phil., President of the Cancer Information and Research Group. We can now harvest the data and therapeutic knowledge accumulated as a result of supplying care for 15% of newly diagnosed cancer patients in the US, utilizing 72 comprehensive cancer centers across the country to provide better outcomes for our patients and our clients."

We selected eResearchTechnology because they offer an integrated electronic solution for managing clinical research studies", noted Terry Murdock, Vice President of US Oncology Research. As we continue to expand and improve the operations of our oncology networks integrated research platform, eResNetTM and eResComTM will provide US Oncology Research a solid foundation for accelerating clinical drug development and for producing quality data in a validated environment."

US Oncology, Inc. represents the nations most extensive oncology network, including cancer research, diagnostic and radiation centers, outpatient blood and marrow stem cell transplant, and pharmaceutical management services. The research group, within US Oncology, offers an integrated platform for conducting Phase I through Phase IV clinical trials for new and approved cancer therapies through US Oncologys community-based physician practices and cancer centers. The US Oncology network operates in 27 states with over 865 affiliated physicians in 496 medical office locations, including 72 integrated cancer centers.

Based in Philadelphia, PA, eResearchTechnology, Inc. (http://www.ert.com), is a business-to-business provider of integrated software applications and technology consulting services to the pharmaceutical, biotechnology and medical device industries. The Company offers Internet and other technology-based solutions designed to streamline the clinical trials process by enabling its customers to automate many parts of a clinical trial. The Company is also a market leader in providing centralized core-diagnostic electrocardiographic services in a global basis.

Statements included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as competitive factors, technological development, market demand, and the Companys ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects, and internal issues in the sponsoring client. Further information on potential factors that could affect the Companys financial results can be found in the Companys Report on Form 10-K filed with the Securities and Exchange Commission (SEC).

                     ###